Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial

In this RCT (n=34; 47 lesions), the addition of 8 weeks of subcutaneous teriparatide (20 µg/day) to calcium and vitamin D supplementation and standard clinical care was associated with a higher rate of lesion resolution at 52 weeks than placebo (45.4% v 33.3%; p=0.013).

Source:

Journal of Clinical Oncology